Research graph
References from Balancing the Dual Mechanisms of Anti-VISTA mAbs for Antitumor Activity: CD8+ T-cell Responses and Fc-Dependent Depletion of VISTA-Expressing Immune Cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer immunotherapies targeting the PD-1 signaling pathway
10.1186/s12929-017-0329-9 · 2017 · External reference
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
10.1084/jem.20100619 · 2011 · External reference
Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models
10.4049/jimmunol.1100660 · 2011 · External reference
Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression
10.1158/2326-6066.cir-18-0489 · 2019 · External reference
VISTA: a target to manage the innate cytokine storm
10.3389/fimmu.2020.595950 · 2021 · External reference
VISTA: a mediator of quiescence and a promising target in cancer immunotherapy
10.1016/j.it.2020.12.008 · 2021 · External reference
Gene array analysis of PD-1H overexpressing monocytes reveals a pro-inflammatory profile
10.1016/j.heliyon.2018.e00545 · 2018 · External reference
PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
10.1126/scitranslmed.aax1159 · 2019 · External reference
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
10.1186/s13045-020-00917-y · 2020 · External reference
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
10.1073/pnas.1811067116 · 2019 · External reference
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
10.1007/s00262-018-2169-1 · 2018 · External reference
High-density infiltration of V-domain immunoglobulin suppressor of T-cell activation up-regulated immune cells in human pancreatic cancer
10.1097/mpa.0000000000001059 · 2018 · External reference
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
10.1038/nm.4308 · 2017 · External reference
Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy
10.1007/s13238-019-0642-z · 2019 · External reference
Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer
10.1158/1078-0432.ccr-17-2542 · 2018 · External reference
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
10.1080/2162402x.2018.1469594 · 2018 · External reference
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
10.1073/pnas.1420370112 · 2015 · External reference
VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
10.1126/science.aay0524 · 2020 · External reference
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers
10.1016/j.cytogfr.2020.02.002 · 2020 · External reference
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
10.1007/s00262-018-2227-8 · 2018 · External reference
VISTA regulates the development of protective antitumor immunity
10.1158/0008-5472.can-13-1506 · 2014 · External reference
VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes
10.1186/s13075-017-1474-y · 2017 · External reference
The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation
10.1038/cmi.2017.148 · 2018 · External reference
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
10.3389/fimmu.2023.1311658 · 2023 · External reference
Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction
10.3389/fimmu.2022.862757 · 2022 · External reference
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response
10.1038/s41467-024-47256-x · 2024 · External reference
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
10.1038/s41598-020-71519-4 · 2020 · External reference
A potent human neutralizing antibody Fc-dependently reduces established HBV infections
10.7554/elife.26738 · 2017 · External reference
A cross-species reactive TIGIT-blocking antibody Fc dependently confers potent antitumor effects
10.4049/jimmunol.1901413 · 2020 · External reference
An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice
10.1038/s41551-022-00956-5 · 2023 · External reference
Antibody-based cancer therapy: successful agents and novel approaches
10.1016/bs.ircmb.2016.10.002 · 2017 · External reference
Structure and functional binding epitope of V-domain Ig suppressor of T cell activation
10.1016/j.celrep.2019.07.073 · 2019 · External reference
VISTA is an acidic pH-selective ligand for PSGL-1
10.1038/s41586-019-1674-5 · 2019 · External reference
Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice
10.1074/jbc.m116.767749 · 2017 · External reference
A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment
10.1002/cyto.a.22012 · 2012 · External reference
Myeloid-derived suppressor cells as regulators of the immune system
10.1038/nri2506 · 2009 · External reference
Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages
10.7150/thno.26888 · 2018 · External reference
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens
10.1002/1521-4141(200211)32:11<3267::aid-immu3267>3.0.co;2-1 · 2002 · External reference
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
10.1080/19420862.2023.2167189 · 2023 · External reference
Epitope and Fc-mediated cross-linking, but not high affinity, are critical for antitumor activity of CD137 agonist antibody with reduced liver toxicity
10.1158/1535-7163.mct-19-0608 · 2020 · External reference
Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner
10.1136/jitc-2021-003382 · 2022 · External reference
Structural basis for zinc-induced activation of a zinc uptake transcriptional regulator
10.1093/nar/gkab432 · 2021 · External reference
182 Highly potent fully human anti-VISTA antibodies–a new target checkpoint inhibitor against immunosuppressive myeloid cells
2020 · External reference
392 Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies
2020 · External reference
